BioCardia (NASDAQ:BCDA – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 323.28% from the company’s previous close. HC Wainwright also issued estimates for BioCardia’s Q4 2023 earnings at ($0.10) EPS, FY2023 earnings at ($0.46) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.43) EPS and FY2027 earnings at ($0.12) EPS.
Separately, Alliance Global Partners cut shares of BioCardia from a “buy” rating to a “neutral” rating in a research note on Friday, July 28th.
BioCardia Trading Down 11.7 %
Institutional Trading of BioCardia
Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in shares of BioCardia in the first quarter valued at $57,000. Vanguard Group Inc. lifted its position in BioCardia by 57.9% during the first quarter. Vanguard Group Inc. now owns 650,523 shares of the company’s stock valued at $1,346,000 after purchasing an additional 238,554 shares during the last quarter. Renaissance Technologies LLC bought a new position in BioCardia during the first quarter valued at $28,000. Millennium Management LLC bought a new position in BioCardia during the second quarter valued at $42,000. Finally, Vontobel Holding Ltd. lifted its position in BioCardia by 93.5% during the second quarter. Vontobel Holding Ltd. now owns 30,751 shares of the company’s stock valued at $82,000 after purchasing an additional 14,856 shares during the last quarter. Institutional investors own 16.46% of the company’s stock.
BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
- Five stocks we like better than BioCardia
- What to Know About Investing in Penny Stocks
- 3 value stocks you shouldn’t let go of this quarter
- Comparing and Trading High PE Ratio Stocks
- 5 must-have next-gen technologies that institutions are buying
- What is the S&P/TSX Index?
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.